An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
Abstract The efficacy of ponesimod and teriflunomide for the treatment of relapsing multiple sclerosis (MS) was compared in a randomized phase III trial. This study explores the exposure‐response (E‐R) relationships of efficacy end points (annualized relapse rate [ARR] and combined unique active les...
Saved in:
Main Authors: | Belén Valenzuela (Author), Per Olsson Gisleskog (Author), Italo Poggesi (Author), Tatiana Sidorenko (Author), Michel Burcklen (Author), Hilke Kracker (Author), Juan Jose Pérez‐Ruixo (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review
by: Katsutoshi Hiramatsu, et al.
Published: (2024) -
Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans
by: Jurcevic S, et al.
Published: (2016) -
The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells
by: Fahimeh Safaeinejad, et al.
Published: (2021) -
Vitamin D Status and Multiple Sclerosis Relapse
by: J Gordon Millichap
Published: (2010) -
Relapse Rate in Pediatric-Onset Multiple Sclerosis
by: J Gordon Millichap
Published: (2009)